While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

A translucent substance and tempered hope poured into me. When it ended, I felt no different than before. ...

Novo Nordisk's semaglutide product to lose patent protection in China next year, according to L.E.K. Consulting Competition in the mainland Chinese market for diabetes and weight loss drugs is set to ...